Skip to main content

Table 1 Patient characteristics and treatments

From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

Mean age 58.4 (range 44–77)
    N = 25 %
Sex Male 17 68
  Female 8 32
TNM Stage T X 4 16
   0 0 0
   1 4 10
   2 7 28
   3 7 28
   4 3 12
  N X 0 0
   0 18 72
   1 0 0
   2 7 28
  M 0 0 0
   1 25 100
Histology Clear cell 21 84  
  Papillary 4 16  
Sites of disease Lung 16 64  
  Lymph node 9 36  
  Soft tissue 7 28  
  Bone 6 24  
  Kidney 5 20  
  Liver 5 20  
  Pancreas 2 8  
  Adrenal 1 4  
Prior Therapy Nephrectomy 23 92  
  Chemotherapy 8 32  
  Immunotherapy 10 40  
  Radiation therapy 2 8  
  Cryoablation 1 4  
  Laser ablation 1 4  
Treatment Characteristics
Vaccination ≤ 2 3 12  
  3–5 14 56  
  ≥ 6 8 32  
No. of IL-2 Cycles 1 4 16  
  2 9 36  
  3 0 0  
  4 9 36